Scancell Share Discussion Threads

[pharmaboy3] 27/6/2024 12:31

Lindy is working her socks off.Can someone who knows this stuff sign up !HTTps://www.linkedin.com/posts/festivalofbiologics_festivalofbiologics-activity-7212009308102782976-g0Hx?utm_source=share&utm_medium=member_android

[marcusl2] 27/6/2024 10:02

SC134 Bispecific


bazookajr
Patent Application



PHARMACEUTICAL | Tue 25 Jun 2024 Seoul, June 26 -- Scancell Ltd has filed a patent application for anti-fucosyl-GM1 antibodies. This invention was developed by Durrant Linda Gillian. The patent application number is KR20227010391 20200902. The patent publication number is KR20220054648 (A). International Patent Classification codes are A61K39/00, A61P35/00 a..

[inanaco] 26/6/2024 15:52

Lindy always takes on the hardest to treat



this will give you an idea of the TME in SCLC

[inanaco] 26/6/2024 15:27

An anti-CD3 monoclonal antibody is one that binds to CD3 on the surface of T cells.

so one arm binds to any t cell

the other arm binds to the Glymab Target

so its bi specific

[inanaco] 26/6/2024 15:18

Hi Ray you have this technically not quite right .. I suspect Scancell is going to be using Modi2 or a homocitrullinated Modi3 to break tolerance to create inflammation

they are specific about breaking tolerance and its falls into the remit of Modi2 perfectly or a specific SCLC peptide

this is what will attract "non" moditope t cells into the cancer which will be attracted to the Mab CD3 ligand and bind. it then kills the cells via The Mab

in this scenario Avidmab is not needed IMHO


RayPointer

Posts: 4,712

Price: 11.125

No Opinion

RE: ImmunoBody/Moditope meets GlymabToday 14:47
It will be really interesting to know what the vaccine is.

If it is a new immunobody vaccine, it would also be interesting if Avidimab is being used twice, i.e., on the mAb and also on the vaccine.

It would also be interesting to know the sequence of events:

For example:

a) mAb attaches to target antigen

b) mAb attracts TCell for same antigen

c) TCell takes over (being much bigger than the mAb) and has multiple TCRs

[marcusl2] 25/6/2024 20:25

Exciting. This would be a combination no-one else has.

Bermudashorts

ImmunoBody/Moditope meets GlymabToday

Scancell are making a couple of very interesting presentations at Pegs Europe in Barcelona in November. We know they've been working on preclinical development of anti glycan mAb SC134 as a T cell redirecting antibody and it seems they've now taken that a step further and are looking at merging a TCB with one of their cancer vaccines. This really is cutting edge stuff. Presentations are as follows:-

Harnessing the Power of Combined Vaccine and T Cell Redirecting Bispecific Antibody to Maximise Anti-Tumour Immunity

Foram Dave, PhD, Research Scientist, R&D, Scancell Ltd.

The success of T cell redirecting antibody in solid tumours is limited due to inherent immune suppressive nature of the tumours, resulting in minimal T cell infiltration. Our proposal merges our in-house vaccine with a T cell redirecting bispecific antibody to overcome this challenge. The vaccine induces initial activation and influx of peripheral T cells, providing an initial boost for CD3 bispecific antibody engagement. Our presentation will highlight the advantageous impact of combining two novel modalities, offering a new approach for cancer treatment.

Fucosyl-GM1: A Versatile Target for SCLC Therapy

Mireille Vankemmelbeke, PhD, Principal Scientist, Biodiscovery, Scancell, Ltd.

SCLC patients are faced with limited treatment options. T cell redirecting antibodies have shown great promise in liquid tumours and are now at the stage where encouraging results are becoming evident in solid tumour settings. ADC modalities have already delivered therapeutic benefit, but careful target selection is warranted for both. The tumour selectivity of the SCLC-associated glycolipid fucosyl-GM1, its expression being virtually absent in normal tissues, combined with evidence of functionality across two modalities open the door additional targeted treatment options for SCLC patients.

[miavoce] 25/6/2024 17:59

900k trade at 11p just posted - somebody is keen. That explains today's rise.

[marcusl2] 25/6/2024 16:13

miavoce, as you say

Maybe the scan of the first iSCIB1+ patient has been done and the results have prompted a few 'in the know' to buy....

or plural. We do know that there have been complete remissions in advanced unresectable melanoma.

[tulley1] 25/6/2024 16:06

Somethings happening

[miavoce] 25/6/2024 15:19

Positive vibes certainly being given off (LD interview, clincaltrials update) - maybe some are now building their positions in advance of what is to come.

[nigelpm] 25/6/2024 14:57

Isn't the news as posted above?

Incredible I thought.

[marcusl2] 25/6/2024 14:36

Tight spread. I was offered 10.75 to sell, 10.8 to buy

Hopefully good news coming!

[marcusl2] 24/6/2024 21:12

Bermudashorts

The SCOPE study record on clinicaltrials.gov has been updated today to include iSCIB1+. Estimated total no. of patients now 130. Also good to see the following changes (as far as I can tell) in study centres:-

1) Guys and St Thomas' are now open for recruitment

2) Christies Manchester has been added but not yet recruiting

3) New centres have opened in Cambridge, Royal Marsden London and Leeds and all are recruiting.

[ivyspivey] 23/6/2024 20:21

Hi Moljen Had a meal in Northumberland Arms last night and it was lovely and such a nice setting on the Coquet.It is sister pub to your local the Blackbird so you are spoiled.

[pharmaboy3] 22/6/2024 15:35

Excellent Forbes article HTTps://www.forbes.com/sites/roberthart/2024/06/04/what-to-know-about-personalized-mrna-cancer-vaccines-after-promising-trials-from-moderna-and-merck/

[marcusl2] 21/6/2024 15:07

Scancell has linked CD3 with fucosyl GM1

Fucosyl-GM1, antigen , is overexpressed on the surface of many cancer cells while its expression is minimal or non-existent in normal tissues

SC134 is a redirecting T cell bispecific undergoing functional analysis and targets fucosyl GM1

Fucosyl-GM1 is known to be expressed in up to 90% of SCLC and, unlike
many other lung cancer antigens, has little or no expression in normal
tissues.



New class of immunotherapy makes the most of existing T cells

But a new class of immunotherapy, called T cell bi-specifics, also known as T cell redirectors, could be changing that. These drugs bind one part of themselves to a tumor cell and the other part to a T cell. Forcing the two cells together has yielded some remarkable results.

An immune checkpoint inhibitor, which takes the brakes off of T cells and allows them to keep working, is much less effective in a cancer that doesn’t have many T cells to begin with.



The FDA accelerated approval of IMDELLTRA is based on results from the Phase 2 trial.

[marcusl2] 20/6/2024 15:55

Very sad news.

[marcusl2] 19/6/2024 18:48

Dear
NIHR Nottm BRC Lung

@NottmBRCLung

We have now commenced a new study: Assessment of FucosylGM1 expression in small cell lung carcinoma via antibody (SC134) binding funded and sponsored by Scancell Limited
@ResearchNuh

#NottinghamisResearch



The main aim of this study is to assess the sugar-lipid distribution pattern on the cancer cells in SCLC cases in order to find which patients with SCLC might benefit from antibody therapy. We need to collect lung biopsy samples from patients being investigated for possible lung cancer so that we can look at any cancer cells in the laboratory and analyse them for the presence and distribution of the sugar-lipid.

[2tyke] 19/6/2024 15:41

Sci102,
The traders which control price probably wouldn't even watch a video about the company progress. Why would they when it makes zilch difference.
In the market....PRICE IS EVERYTHING.
You think it isn't at your own peril and loss.
Big investors ? Irrelevant to a share price They matter to the company..not the share price
The huge profits are with real assets like Bitcoin. Trader sentiment is sky-high.
You'll find little investors like inane in stocks like this . Sitting in a car park counting pennies...lol

[inanaco] 19/6/2024 13:11

yes i am clueless ... but rich enough to sit on 1.5m shares waiting for my clueless moment which is not so clue less as we think due to

"probability"

something i was clueless about up until an "expert" appeared

One expert said ... "you cant predict"

so I proved that wrong

another expert said ... we have to average the cancers shrinkage and remove all those that did not see shrinkage to make the maths that he created work

so i proved that wrong

The Sp ... about as predictable as human behaviour

[sci102] 19/6/2024 12:46

The share price did not react further and instead fell back to the pre RNS levels because the CEO f-ed up the interview by assuming that investors are the same as the general public that visits her academic lab to hear from the scientists how expensive is what they are doing and how they could use more support/donations.

High profile investors that could have made a difference are not the general public ffs, when you tell them that scib1 recruitment was slow because people were waiting for iscib1+, they are neither impressed nor amused. They take it as a straight lie, because it is. And that is on top of all the other lies she said before.

Sadly after 20 years, she still does not understand how to run a public company and she should either quit the CEO position or at least get some training.

[2tyke] 19/6/2024 12:29

Ruckrover,..
Yes, I understood the point you were making. I wasn't criticising although it may have read as such.
It's just that most of the peeps on here don't appreciate what moves SP's. They think it's external things like news ...even though every time good news is released, the share price declines further..lol. They suffer from lack of intellectual honesty !
.................
Inane, Lindy is NOT a technical analyst. She is a scientist.
She is no doubt a very clever lady, and therefore if you asked her about SP's she would almost certainly give you an honest answer of....I don't understand SP's.
YOU don't either ..so don't pretend you do.
Your as clueless as Mr marking (wake me up at 40p)time...lol